Experimental CAR-T therapy takes on debilitating nerve disease
NCT ID NCT07592754
First seen May 20, 2026 · Last updated May 20, 2026
Summary
This early study tests a new treatment called KSVCBD, a type of CAR-T cell therapy, for people with a rare autoimmune disease called neuromyelitis optica spectrum disorder (NMOSD) that has not responded well to standard treatments. The goal is to see if the therapy is safe and if it can reduce relapses and disability. About 18 adults who test positive for AQP4 antibodies and have had at least one relapse in the past year will receive the treatment and be closely monitored.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for NEUROMYELITIS OPTICA SPECTRUM DISEASE (NMOSD) are added.
Genom att skicka in godkänner du våra Användarvillkor
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
Genom att skicka in godkänner du våra Användarvillkor
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Chinese PLA General Hospital
Beijing, Beijing Municipality, 100853, China
Contact Phone: •••-•••-•••• Email: •••••@•••••
Conditions
Explore the condition pages connected to this study.